GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » EV-to-FCF

Cardiff Oncology (STU:XE7C) EV-to-FCF : -3.03 (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cardiff Oncology's Enterprise Value is €85.66 Mil. Cardiff Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-28.31 Mil. Therefore, Cardiff Oncology's EV-to-FCF for today is -3.03.

The historical rank and industry rank for Cardiff Oncology's EV-to-FCF or its related term are showing as below:

STU:XE7C' s EV-to-FCF Range Over the Past 10 Years
Min: -33.33   Med: -1.36   Max: 2.57
Current: -3.04

During the past 13 years, the highest EV-to-FCF of Cardiff Oncology was 2.57. The lowest was -33.33. And the median was -1.36.

STU:XE7C's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs STU:XE7C: -3.04

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Cardiff Oncology's stock price is €3.265. Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.832. Therefore, Cardiff Oncology's PE Ratio for today is At Loss.


Cardiff Oncology EV-to-FCF Historical Data

The historical data trend for Cardiff Oncology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology EV-to-FCF Chart

Cardiff Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -32.17 -4.93 1.15 0.21

Cardiff Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.64 0.50 0.21 -5.67

Competitive Comparison of Cardiff Oncology's EV-to-FCF

For the Biotechnology subindustry, Cardiff Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's EV-to-FCF falls into.



Cardiff Oncology EV-to-FCF Calculation

Cardiff Oncology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=85.657/-28.314
=-3.03

Cardiff Oncology's current Enterprise Value is €85.66 Mil.
Cardiff Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology  (STU:XE7C) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cardiff Oncology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.265/-0.832
=At Loss

Cardiff Oncology's share price for today is €3.265.
Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.832.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cardiff Oncology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology (STU:XE7C) Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines